Chinese General Practice ›› 2023, Vol. 26 ›› Issue (35): 4412-4418.DOI: 10.12114/j.issn.1007-9572.2023.0167
• Article • Previous Articles Next Articles
Received:
2023-02-08
Revised:
2023-06-10
Published:
2023-12-15
Online:
2023-07-25
Contact:
ZHOU Jie, LI Xiaomiao
About author:
通讯作者:
周洁, 李晓苗
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0167
组别 | 例数 | 性别(男/女) | 年龄(岁) | 糖尿病病程(年) | 体表面积(m2) | BMI(kg/m2) | 心率(次/min) | 高血压〔例(%)〕 | 收缩压(mmHg) | 舒张压(mmHg) | 糖化血红蛋白(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
单纯T2DM组 | 76 | 50/26 | 52.0±14.9 | 8.40±6.83 | 1.78±0.19 | 24.2±3.9 | 74.24±11.62 | 28(36.8) | 132±16 | 77±9 | 8.21±1.83 |
T2DM+C(1)组 | 37 | 23/14 | 53.2±13.8 | 9.33±6.48 | 1.73±0.18 | 23.5±3.1 | 75.08±11.33 | 15(40.5) | 130±17 | 78±9 | 9.30±1.74a |
T2DM+C(2~3)组 | 37 | 23/14 | 56.7±10.9 | 14.83±6.93ab | 1.81±0.19 | 24.7±3.8 | 81.44±13.75ab | 25(67.6)ab | 139±22 | 80±15 | 9.52±2.55a |
检验统计量值 | 0.214c | 1.438 | 11.407 | 1.448 | 1.084 | 4.524 | 9.935c | 2.516 | 0.738 | 6.777 | |
P值 | 0.898 | 0.241 | <0.001 | 0.238 | 0.341 | 0.012 | 0.007 | 0.084 | 0.480 | 0.002 | |
组别 | 空腹血糖(mmol/L) | 总胆固醇(mmol/L) | 三酰甘油〔M(P25,P75),mmol/L〕 | HDL-C(mmol/L) | LDL-C(mmol/L) | 尿酸(μmol/L) | 血肌酐(μmol/L) | 尿微量白蛋白〔M(P25,P75),mg/L〕 | UACR〔M(P25,P75),mg/mmol〕 | ||
单纯T2DM组 | 10.56±4.10 | 3.99±1.01 | 1.34(0.86,1.76) | 1.14±0.42 | 2.32±1.04 | 321.25±79.62 | 64.77±22.96 | 10.70(7.80,13.80) | 1.26(0.74,2.01) | ||
T2DM+C(1)组 | 12.64±5.55a | 3.91±1.15 | 1.34(0.92,1.92) | 1.01±0.23 | 2.32±0.95 | 315.81±82.20 | 65.70±17.86 | 13.00(8.30,23.60) | 1.58(1.20,3.52) | ||
T2DM+C(2~3)组 | 13.15±5.52a | 4.30±1.63 | 1.47(0.98,2.68) | 1.13±0.57 | 2.52±1.47 | 327.86±87.84 | 88.06±68.69ab | 29.50(10.08,108.98)ab | 4.84(1.65,20.41)ab | ||
检验统计量值 | 4.428 | 1.035 | 3.376d | 1.285 | 0.431 | 1.196 | 4.810 | 17.221d | 29.850d | ||
P值 | 0.014 | 0.358 | 0.185 | 0.280 | 0.650 | 0.822 | 0.010 | <0.001 | <0.001 | ||
组别 | eGFR〔M(P25,P75),mL·min-1·(1.73 m2)-1〕 | ACEI/ARB〔例(%)〕 | β受体阻滞剂〔例(%)〕 | CCB〔例(%)〕 | 他汀类〔例(%)〕 | SGLT-2i〔例(%)〕 | DPP-4i〔例(%)〕 | 二甲双胍〔例(%)〕 | 阿卡波糖〔例(%)〕 | 胰岛素〔例(%)〕 | |
单纯T2DM组 | 122.35(103.27,143.66) | 16(21.1) | 3(3.9) | 12(15.8) | 18(23.7) | 7(9.2) | 8 (10.5) | 51(67.1) | 31(40.8) | 36(47.4) | |
T2DM+C(1)组 | 115.85(106.86,139.81) | 6(16.2) | 1(2.7) | 7(18.9) | 7(18.9) | 2(5.4) | 5(13.5) | 26(70.3) | 8(21.6) | 19(51.4) | |
T2DM+C(2~3)组 | 106.99(92.11,123.21) | 12(32.4) | 1(2.7) | 12(32.4) | 10(27.0) | 5(13.5) | 4(10.8) | 28(75.7) | 14(37.8) | 26(70.3) | |
检验统计量值 | 2.486d | 2.093c | 0.180c | 4.296c | 0.690c | 1.440c | 0.234c | 0.872c | 4.136c | 5.393c | |
P值 | 0.288 | 0.351 | 0.914 | 0.117 | 0.708 | 0.487 | 0.889 | 0.647 | 0.126 | 0.067 |
Table 1 Comparison of general data and biochemical indicators among the three groups
组别 | 例数 | 性别(男/女) | 年龄(岁) | 糖尿病病程(年) | 体表面积(m2) | BMI(kg/m2) | 心率(次/min) | 高血压〔例(%)〕 | 收缩压(mmHg) | 舒张压(mmHg) | 糖化血红蛋白(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
单纯T2DM组 | 76 | 50/26 | 52.0±14.9 | 8.40±6.83 | 1.78±0.19 | 24.2±3.9 | 74.24±11.62 | 28(36.8) | 132±16 | 77±9 | 8.21±1.83 |
T2DM+C(1)组 | 37 | 23/14 | 53.2±13.8 | 9.33±6.48 | 1.73±0.18 | 23.5±3.1 | 75.08±11.33 | 15(40.5) | 130±17 | 78±9 | 9.30±1.74a |
T2DM+C(2~3)组 | 37 | 23/14 | 56.7±10.9 | 14.83±6.93ab | 1.81±0.19 | 24.7±3.8 | 81.44±13.75ab | 25(67.6)ab | 139±22 | 80±15 | 9.52±2.55a |
检验统计量值 | 0.214c | 1.438 | 11.407 | 1.448 | 1.084 | 4.524 | 9.935c | 2.516 | 0.738 | 6.777 | |
P值 | 0.898 | 0.241 | <0.001 | 0.238 | 0.341 | 0.012 | 0.007 | 0.084 | 0.480 | 0.002 | |
组别 | 空腹血糖(mmol/L) | 总胆固醇(mmol/L) | 三酰甘油〔M(P25,P75),mmol/L〕 | HDL-C(mmol/L) | LDL-C(mmol/L) | 尿酸(μmol/L) | 血肌酐(μmol/L) | 尿微量白蛋白〔M(P25,P75),mg/L〕 | UACR〔M(P25,P75),mg/mmol〕 | ||
单纯T2DM组 | 10.56±4.10 | 3.99±1.01 | 1.34(0.86,1.76) | 1.14±0.42 | 2.32±1.04 | 321.25±79.62 | 64.77±22.96 | 10.70(7.80,13.80) | 1.26(0.74,2.01) | ||
T2DM+C(1)组 | 12.64±5.55a | 3.91±1.15 | 1.34(0.92,1.92) | 1.01±0.23 | 2.32±0.95 | 315.81±82.20 | 65.70±17.86 | 13.00(8.30,23.60) | 1.58(1.20,3.52) | ||
T2DM+C(2~3)组 | 13.15±5.52a | 4.30±1.63 | 1.47(0.98,2.68) | 1.13±0.57 | 2.52±1.47 | 327.86±87.84 | 88.06±68.69ab | 29.50(10.08,108.98)ab | 4.84(1.65,20.41)ab | ||
检验统计量值 | 4.428 | 1.035 | 3.376d | 1.285 | 0.431 | 1.196 | 4.810 | 17.221d | 29.850d | ||
P值 | 0.014 | 0.358 | 0.185 | 0.280 | 0.650 | 0.822 | 0.010 | <0.001 | <0.001 | ||
组别 | eGFR〔M(P25,P75),mL·min-1·(1.73 m2)-1〕 | ACEI/ARB〔例(%)〕 | β受体阻滞剂〔例(%)〕 | CCB〔例(%)〕 | 他汀类〔例(%)〕 | SGLT-2i〔例(%)〕 | DPP-4i〔例(%)〕 | 二甲双胍〔例(%)〕 | 阿卡波糖〔例(%)〕 | 胰岛素〔例(%)〕 | |
单纯T2DM组 | 122.35(103.27,143.66) | 16(21.1) | 3(3.9) | 12(15.8) | 18(23.7) | 7(9.2) | 8 (10.5) | 51(67.1) | 31(40.8) | 36(47.4) | |
T2DM+C(1)组 | 115.85(106.86,139.81) | 6(16.2) | 1(2.7) | 7(18.9) | 7(18.9) | 2(5.4) | 5(13.5) | 26(70.3) | 8(21.6) | 19(51.4) | |
T2DM+C(2~3)组 | 106.99(92.11,123.21) | 12(32.4) | 1(2.7) | 12(32.4) | 10(27.0) | 5(13.5) | 4(10.8) | 28(75.7) | 14(37.8) | 26(70.3) | |
检验统计量值 | 2.486d | 2.093c | 0.180c | 4.296c | 0.690c | 1.440c | 0.234c | 0.872c | 4.136c | 5.393c | |
P值 | 0.288 | 0.351 | 0.914 | 0.117 | 0.708 | 0.487 | 0.889 | 0.647 | 0.126 | 0.067 |
组别 | 例数 | LVEF(%) | 左心室缩短分数(%) | 每搏量(mL) | E | A | E' | E/A比值〔M(P25,P75)〕 | E/E'比值 | GLS(%) |
---|---|---|---|---|---|---|---|---|---|---|
单纯T2DM组 | 76 | 60.96±4.20 | 32.88±3.47 | 46.52±8.00 | 67.93±15.45 | 76.88±21.21 | 7.81±2.68 | 0.85(0.68,1.20) | 9.86±3.46 | 19.12±3.23 |
T2DM+C(1)组 | 37 | 59.58±5.25 | 31.45±4.02 | 47.52±9.47 | 61.30±14.75 | 73.33±20.83 | 7.07±2.99 | 0.81(0.74,1.12) | 9.53±3.60 | 16.93±3.61a |
T2DM+C(2~3)组 | 37 | 58.71±4.67 | 30.77±4.06a | 49.06±10.19 | 68.19±16.23 | 86.23±12.95ab | 6.65±2.12 | 0.66(0.63,0.92) | 11.47±3.21 | 16.78±2.74a |
F(Z)值 | 2.840 | 3.919 | 0.876 | 2.146 | 3.224 | 1.882 | 4.678c | 1.917 | 9.282 | |
P值 | 0.062 | 0.022 | 0.419 | 0.121 | 0.043 | 0.157 | 0.096 | 0.153 | <0.001 |
Table 2 Comparison of echocardiographic characteristics among the three groups
组别 | 例数 | LVEF(%) | 左心室缩短分数(%) | 每搏量(mL) | E | A | E' | E/A比值〔M(P25,P75)〕 | E/E'比值 | GLS(%) |
---|---|---|---|---|---|---|---|---|---|---|
单纯T2DM组 | 76 | 60.96±4.20 | 32.88±3.47 | 46.52±8.00 | 67.93±15.45 | 76.88±21.21 | 7.81±2.68 | 0.85(0.68,1.20) | 9.86±3.46 | 19.12±3.23 |
T2DM+C(1)组 | 37 | 59.58±5.25 | 31.45±4.02 | 47.52±9.47 | 61.30±14.75 | 73.33±20.83 | 7.07±2.99 | 0.81(0.74,1.12) | 9.53±3.60 | 16.93±3.61a |
T2DM+C(2~3)组 | 37 | 58.71±4.67 | 30.77±4.06a | 49.06±10.19 | 68.19±16.23 | 86.23±12.95ab | 6.65±2.12 | 0.66(0.63,0.92) | 11.47±3.21 | 16.78±2.74a |
F(Z)值 | 2.840 | 3.919 | 0.876 | 2.146 | 3.224 | 1.882 | 4.678c | 1.917 | 9.282 | |
P值 | 0.062 | 0.022 | 0.419 | 0.121 | 0.043 | 0.157 | 0.096 | 0.153 | <0.001 |
模型 | 单纯T2DM组与T2DM+C(1)组 | 单纯T2DM组与T2DM+C(2~3)组 | ||
---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | |
模型1 | 0.805(0.705,0.920) | 0.001 | 0.793(0.693,0.907) | <0.001 |
模型2 | 0.785(0.684,0.902) | <0.001 | 0.764(0.663,0.880) | <0.001 |
模型3 | 0.744(0.601,0.920) | 0.006 | 0.707(0.525,0.952) | 0.022 |
Table 3 Logistic regression analysis of the relationship between diabetic microvascular complications and GLS
模型 | 单纯T2DM组与T2DM+C(1)组 | 单纯T2DM组与T2DM+C(2~3)组 | ||
---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | |
模型1 | 0.805(0.705,0.920) | 0.001 | 0.793(0.693,0.907) | <0.001 |
模型2 | 0.785(0.684,0.902) | <0.001 | 0.764(0.663,0.880) | <0.001 |
模型3 | 0.744(0.601,0.920) | 0.006 | 0.707(0.525,0.952) | 0.022 |
模型 | 无高血压 | 有高血压 | ||
---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | |
模型1 | 0.762(0.638,0.910) | 0.003 | 0.843(0.725,0.981) | 0.027 |
模型2 | 0.719(0.592,0.873) | 0.001 | 0.828(0.706,0.970) | 0.019 |
模型3 | 0.739(0.558,0.979) | 0.035 | 0.556(0.321,0.963) | 0.036 |
Table 4 Logistic regression analysis of the relationship between diabetic microvascular complications and left ventricular GLS based on stratification of hypertension
模型 | 无高血压 | 有高血压 | ||
---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | |
模型1 | 0.762(0.638,0.910) | 0.003 | 0.843(0.725,0.981) | 0.027 |
模型2 | 0.719(0.592,0.873) | 0.001 | 0.828(0.706,0.970) | 0.019 |
模型3 | 0.739(0.558,0.979) | 0.035 | 0.556(0.321,0.963) | 0.036 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志,2021,13(4):315-409.
|
[11] |
|
[12] |
|
[13] |
贾懿劼,薛耀明. 《中国糖尿病肾脏病防治指南》(2021年版)解读[J]. 临床内科杂志,2022,39(5):303-306. DOI:10.3969/j.issn.1001-9057.2022.05.004.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
韩红生,郑哲岚,王群苹,等. 二维斑点追踪技术评价2型糖尿病合并微血管病变患者左心室收缩功能的价值[J]. 中华医学超声杂志(电子版),2018,15(3):178-183. DOI:10.3877/cma.j.issn.1672-6448.2018.03.004.
|
[24] |
拓胜军,高雨洁,井一淑,等. 二维斑点追踪技术评估糖尿病前期患者左心室亚临床收缩功能价值[J]. 中华实用诊断与治疗杂志,2016,30(10):1025-1027. DOI:10.13507/j.issn.1674-3474.2016.10.032.
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
No related articles found! |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||